Current Management of Chronic Myeloid Leukemia with Tyrosine Kinase Inhibitors
The clinical outcomes and survival of tyrosine kinase inhibitor (TKI)-treated patients with chronic myeloid leukemia (CML) have been significantly improved. The aim of this editorial is to outline critical steps of TKI administration practices during the long-term clinical course of CML based on dat...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Galenos Publishing House
2013-09-01
|
| Series: | Turkish Journal of Hematology |
| Subjects: | |
| Online Access: | https://jag.journalagent.com/z4/download_fulltext.asp?pdir=tjh&un=TJH-34635 |
| _version_ | 1797912461178830848 |
|---|---|
| author | İbrahim C. Haznedaroğlu |
| author_facet | İbrahim C. Haznedaroğlu |
| author_sort | İbrahim C. Haznedaroğlu |
| collection | DOAJ |
| description | The clinical outcomes and survival of tyrosine kinase inhibitor (TKI)-treated patients with chronic myeloid leukemia (CML) have been significantly improved. The aim of this editorial is to outline critical steps of TKI administration practices during the long-term clinical course of CML based on data obtained from randomized clinical trials and international recommendations. The efficacy of TKI treatment, TKI side effects, off-target complications, and long-term morbidities due to both the disease and the drug are common arguments in the management of CML. Complete hematological response, early complete cytogenetic response, faster major molecular response, and deeper, more durable molecular responses (MR4, MR4.5, MR5) are the ultimate goals for TKI-receiving patients with CML. |
| first_indexed | 2024-04-10T11:56:19Z |
| format | Article |
| id | doaj.art-da148cabb9394ec49288602698c42a9e |
| institution | Directory Open Access Journal |
| issn | 1308-5263 |
| language | English |
| last_indexed | 2024-04-10T11:56:19Z |
| publishDate | 2013-09-01 |
| publisher | Galenos Publishing House |
| record_format | Article |
| series | Turkish Journal of Hematology |
| spelling | doaj.art-da148cabb9394ec49288602698c42a9e2023-02-15T16:16:48ZengGalenos Publishing HouseTurkish Journal of Hematology1308-52632013-09-0130324725510.4274/Tjh.2013.0108TJH-34635Current Management of Chronic Myeloid Leukemia with Tyrosine Kinase Inhibitorsİbrahim C. Haznedaroğlu0Hacettepe University Medical School, Department Of Hematology, Ankara, TurkeyThe clinical outcomes and survival of tyrosine kinase inhibitor (TKI)-treated patients with chronic myeloid leukemia (CML) have been significantly improved. The aim of this editorial is to outline critical steps of TKI administration practices during the long-term clinical course of CML based on data obtained from randomized clinical trials and international recommendations. The efficacy of TKI treatment, TKI side effects, off-target complications, and long-term morbidities due to both the disease and the drug are common arguments in the management of CML. Complete hematological response, early complete cytogenetic response, faster major molecular response, and deeper, more durable molecular responses (MR4, MR4.5, MR5) are the ultimate goals for TKI-receiving patients with CML.https://jag.journalagent.com/z4/download_fulltext.asp?pdir=tjh&un=TJH-34635chronic myeloid leukemiatyrosine kinase inhibitorimatinibnilotinibdasatinibbosutinibponatinib |
| spellingShingle | İbrahim C. Haznedaroğlu Current Management of Chronic Myeloid Leukemia with Tyrosine Kinase Inhibitors Turkish Journal of Hematology chronic myeloid leukemia tyrosine kinase inhibitor imatinib nilotinib dasatinib bosutinib ponatinib |
| title | Current Management of Chronic Myeloid Leukemia with Tyrosine Kinase Inhibitors |
| title_full | Current Management of Chronic Myeloid Leukemia with Tyrosine Kinase Inhibitors |
| title_fullStr | Current Management of Chronic Myeloid Leukemia with Tyrosine Kinase Inhibitors |
| title_full_unstemmed | Current Management of Chronic Myeloid Leukemia with Tyrosine Kinase Inhibitors |
| title_short | Current Management of Chronic Myeloid Leukemia with Tyrosine Kinase Inhibitors |
| title_sort | current management of chronic myeloid leukemia with tyrosine kinase inhibitors |
| topic | chronic myeloid leukemia tyrosine kinase inhibitor imatinib nilotinib dasatinib bosutinib ponatinib |
| url | https://jag.journalagent.com/z4/download_fulltext.asp?pdir=tjh&un=TJH-34635 |
| work_keys_str_mv | AT ibrahimchaznedaroglu currentmanagementofchronicmyeloidleukemiawithtyrosinekinaseinhibitors |